An interventional study of Implantable loop recorders system Reveal ICM LINQ®, in Aortic Valve Disease and Conduction Disturbances, sponsored by Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Aortic Valve Disease with a site in Canada — 2 open to participants now, 2 under way, none of them phase 3. Aortic Valve Disease · Canada.
Among the 18 studies in Aortic Valve Disease with a site in Canada, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2014, is one of 11 with no phase, and was the 9th registered.
235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.
Browse Aortic Valve Disease studies →2 of the 18 studies in Aortic Valve Disease with a site in Canada are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Canada, United States, Australia and 10 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 111 across 125 interventional studies indexed under Aortic Valve Disease.
Median enrollment 267 across the 14 interventional studies, 90 across the 4 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec has 3 studies filed under Aortic Valve Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Disease with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Aortic Valve Disease with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the incidence and predictors of high degree or complete atrioventricular block (AVB) (paroxysmal or persistent) in patients with new-onset persistent left bundle branch block (NOP-LBBB) following transcatheter aortic valve implantation (TAVI) and to evaluate the usefulness of the Reveal LINQ® insertable Cardiac Monitor (ICM) (Medtronic, Inc., Minneapolis, USA) for the detection of significant arrhythmias in patients with NOP-LBBB following TAVI.
This is a prospective observational study including patients undergoing TAVI with either self- or balloon-expandable valves. After the procedure, patients will be on ECG monitoring during the hospitalization period (or at least 72 hours), and an ECG will be performed daily until hospital discharge in all patients. Patients with new-onset persistent LBBB at hospital discharge (new-onset LBBB of a duration of at least 48 h which persists at hospital discharge, at least 3 days and up to 15 days after the procedure) will receive an implantable loop recorder Reveal ICM LINQ®, which will be implanted subcutaneously to record adequate QRS complexes and P waves. The patients will be followed in outpatient clinic visits at 1, 12, 24 and 36 months after TAVR, or if symptoms suggestive of cardiac origin or relevant arrhythmic events occur. The device will be manually interrogated in each visit. Phone contacts will be also carried out every three months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Patients undergoing TAVI with either balloon or self-expandable valves who develop new-onset LBBB persistent at hospital discharge, at least 3 days after the procedure
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Implantable loop recorders system Reveal ICM LINQ®,
-Rate and time of onset of high degree or complete AVB
Time frame: 1Year
-Incidence of arrhythmic events identified by the IRL leading to a change in treatment or major adverse event
Time frame: 1 Year
-Rate of high degree or complete of AVB
Time frame: Within the first month after TAVI procedure
-Rate of high degree or complete of AVB
Time frame: 6-month follow-up
-Rate of high degree or complete AVB
Time frame: 24-month follow-up
-Rate of high degree or complete AVB
Time frame: 36-month follow-up
-Electrocardiographic and device-related factors predicting the occurence of high degree or complete AVB in patients with new-onset LBBB after TAVI
Periprocedural results of TAVI of patients with NOP-LVV will be used to characterize predictors of high degree or complete AVB. Moreover, electrocardiographic characteristics at hospital discharge of patients with NOP-LVV will also be used to characterize predictors of high degree or complete AVB.
Time frame: Within the first 3 years following TAVI procedure
-Rate of new atrial fibrillation or ventricular arrhythmias
Time frame: Within the first 3 years following TAVI procedure
-Changes in left ventricular function and mitral regurgitation over time
Time frame: Within the first 3 years following TAVI procedure
The record gives a start of Jan 2014, a primary completion of May 2020 and a completion of Jul 2027. It does not say whether these dates are actual or estimated.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec